Onconova's myelodysplastic syndrome drug enters Phase III trial

05/12/2013 | Pharmaceutical Business Review Online

Onconova Therapeutics has finished enrolling 270 myelodysplastic syndrome patients for a late-stage trial of rigosertib. The trial will be carried out in the U.S. and five countries in the European Union, with overall survival as main endpoint. The firm expects to release data either in the fourth quarter of this year or the first quarter of next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX